1. Management and Key Leader Group

Management and Key Leader Group

Introducing Management and
Key Leader Group of Helixmith.

개인정보처리방침

닫기

이메일무단수집거부

닫기

Sunyoung KIM, D. Phil
CEO, Representative Director

  • 1996~present

    CEO of Helixmith

  • 2014~2016

    Director of National Research Council of Science & Technology (NST)

  • 2013~2015

    President of Seoul National University Bio-MAX Institute

  • 2010~2011

    Investment manager in fusion new industry sector of R&D strategy planning group, ministry of knowledge economy

  • 2006~2008

    The 1st and 2nd Chairman of the Korean Society of Gene Therapy

  • 1992~2018

    Professor, Biological Sciences, Seoul National University

  • 1990~1992

    Assistant Professor, Harvard Medical School

  • 1987~1989

    Postdoctoral fellowship, MIT Whitehead Institute

  • 1986

    PhD, Molecular Genetics, the University of Oxford

  • 1984

    Master, Microbiology/Molecular Genetics, Harvard University

  • 1982

    Master, Bioengineering, MIT

  • 1978

    BS, Microbiology, Seoul National University

Sunyoung KIM D. Phil

Seungshin Yu, Ph.D.
CTO, Representative Director

  • 2020~present

    CTO of Helixmith

  • 2008~2019

    Former Director of Bio Headquarter, President of Research Institute

  • 2005~2008

    Department Head, Takara Bio Research Institute

  • 1995~1997

    Postdoctoral fellowship, MIT Whitehead Institute

  • 1984~1995

    BS, Microbiology, Seoul National University, Master/Ph.D, Virology at Seoul National University

Seungshin Yu CTO

Sinyoung KIM
COO, Representative Director

  • 2021~present

    COO of Helixmith

  • 2010~2020

    CEO/Vice Chairman, Sejong Telecom Incorporated

  • 2007~2010

    CEO, Boas International Capital

  • 2005~2007

    CEO, Solomon Capital

  • 2003~2005

    CEO, Zionex Inc

  • 1999~2002

    Executive Director, Goldman Sachs Inc.

  • 1998~1999

    Vice President, Lone Star Funds

  • 1996~1998

    Director, Dongah Group

  • 1983~1996

    Planning Office, Samsung C&T Corp., Secretary’s Office, Samsung Group

  • 1984

    BS, Economics, Yonsei University

Sinyoung KIM COO

Key Leader Group

  • Process Development & Manufacturing TechnologiesKyungdong Bae

  • Clinical DevelopmentYoungjoo Park

  • Phytotherapeutics, R&DDoo suk Lee

  • Corporate DevelopmentJehee Suh

  • Head of Financial Administration, Executive DirectorSOONMOON JANG

  • Clinical DevelopmentWilliam K. Schmidt

  • Clinical OperationsAdam Ruskin

  • Head of MedicalWilliam O. Frank

  • Regulatory AffairsCindy Fisher

  • Quality AssuranceJose Zapata

Key Leader Group

Process Development & Manufacturing TechnologiesKyungdong Bae

  • Director & Co-chairman, Korean Society for Biotechnology and Bioengineering
  • Member of Expert Committee at Advanced Therapy and Expert Panel at Plasmid DNA, US Pharmacopeia (2020~2025 cycle)
  • Director & Head of Vaccine Process and Analytical Development, Janssen Vaccine Korea
  • Adjunct professor, Department of Bioengineering, Graduate School of Inha University
  • BS/MA/PhD, Department of Chemical and Biological Engineering, Inha University

Key Leader Group

Clinical DevelopmentYoungjoo Park

  • Senior Director for External Cooperation and Business Development, Korea National Enterprise for Clinical Trials, Affiliation of Ministry of Health and Welfare
  • Sanofi, Head of Clinical Study Unit, R&D
  • MSD, Senior Manager for biostatistics, data management, pharmacovigilance, and medical writing
  • Master of Public Health, Ph.D. in Epidemiology, Seoul National University
  • BS, Life Science, Ewha Womans University

Key Leader Group

Phytotherapeutics, R&DDoo suk Lee

  • Nature Korean Medicine Clinic
  • Korean Medical License (Ministry of Health and Welfare)
  • Ph.D., Department of Biological Sciences, Seoul National University
  • BS, Department of Korean Medicine, College of Korean Medicine, Dongguk University

Key Leader Group

Corporate DevelopmentJehee Suh

  • CAR-T cell therapy subsidiary of Helixmith
  • Former Head of Global Business Strategy and Business Development
  • Partner at McKinsey & Company (Pharmaceuticals & Medical Products)
  • Marketing, Novartis Korea
  • Wharton MBA, major in Healthcare Management
  • BS, Biology, Seoul National University

Key Leader Group

Head of Financial Administration, Executive DirectorSOONMOON JANG

  • Executive director: Ansell Korea, DentsplySirona Korea, PharmaLink Korea, Quintiles Transnational Korea
  • Head of Cap Gemini Ernst&Young Korea
  • Manager of Sandvik Korea, Hanglas
  • AICPA certificate
  • BS, Department of accounting, Sungkyunkwan University

Key Leader Group

Clinical DevelopmentWilliam K.Schmidt

  • President, North Star Consulting
  • Chief Medical Officer, Ensysce Bioscience
  • Vice President of Clinical Development, EicOsis
  • Postdoctoral training, Boston University School of Medicine
  • PhD in Pharmacology, UC San Francisco

Key Leader Group

Clinical OperationsAdam Ruskin

  • Sr. Contractor (Clinical Operations), ApprovedCRO
  • Head (Clinical Development), Asuragen
  • VP (Clinical Operations), LabCRO, Inc.
  • Sr. Director (Clinical Operations), Genturadx
  • Sr. Director (Clinical Operations), Emergent BioSolutions
  • Director (Clinical Operations), Emergent BioSolutions Inc Sr. Director (Clinical Research and Operations), Maxygen
  • Director (Clinical Operations), Cerexa
  • Principal Program Manager, PPD
  • Department Lead (Clinical Operations, Biostatistics and Data Management), Natus Medical
  • Director (Clinical Operations), Ischemia Research and Education Foundation
  • Epidemiologist, Fulton-DeKalb Hospital Authority
  • Epidemiologist, Centers for Disease Control
  • Epidemiology (MPH, PhD), Emory University
  • Veterinary Medicine (DVM), Kansas State University
  • Animal Bioscience/Environmental Resource Management (B.S.), Penn State University

Key Leader Group

Head of MedicalWilliam O. Frank

  • Vice President, Retrophin Inc.
  • Vice President, Vital Therapies Inc.
  • Senior Medical Director and Vice President, Santarus Inc.
  • Senior Medical Director, Novartis
  • Director, Clinical Research & Development, Sandoz
  • Group Director, Clinical Development & Medical Affairs, Smith-Kline Beecham Pharmaceutical Corporation
  • MD, Temple University
  • BS in Chemistry and Biological Sciences, University of Pittsburgh

Key Leader Group

Regulatory AffairsCindy Fisher

  • Director, Regulatory Affairs, Vical Incorporated.
  • Principal Scientist, Structural Bioinformatics, Inc.
  • Postdoctoral Fellow, Scripps Research Institute
  • Postdoctoral Fellow, Agouron Institute
  • PhD in Physical Organic Chemistry, UC Irvine
  • BS in Chemistry, UCLA

Key Leader Group

Quality AssuranceJose Zapata

  • Sr. Director (QA), Histogen
  • Director Quality Assurance, Quality System, Conatus Pharma
  • Director (QA), Peregrine Pharmaceuticals Inc.
  • Director (QA-Renal division), OPKO (Formally Cytochroma)
  • Associate Director (QA), Immtech Pharmaceutical
  • Director (QA & Regulatory Affairs), Resource Optimization Innovation
  • Director (QA), Triad Pharmaceuticals
  • Quality Assurance Director (Fluid Air), PharmaPro Services
  • Manager (QA), Opportunity Medical
  • Quality & Regulatory (M.S.), Temple University – Lewis Katz School of Medicine
  • Biological Science (B.S.), DePaul University